Meeting ReportCardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO)
Keywords
Cited by (0)
PHP has received research funding from Satellite Health Care. BLK has received research funding from Bristol-Myers Squibb and Genzyme and is a paid advisor for Litholink (Lab Corp). RGH has received research consulting fees from Boehringer Ingleheim. RWA is a paid advisor for Atritech. RSP receives research support, speaker's fees, and consulting fees from Medtronic. K-UE has received lecture or consulting fees from Amgen, Bayer, Genzyme and GSK, Johnson & Johnson, Novartis, Roche, Sanofi-Aventis. CAH has received research support from Amgen and Johnson & Johnson and honoraria from UpToDate, is a consultant for Amgen, CorMedix, Abbott Labs, FibroGen, Affymax, Fresenius, and Merck, and has equity interest in Cambridge Heart, Merck, Boston Scientific, and J&J. All other authors declared no competing interests. This conference was sponsored by KDIGO and was partially supported by unrestricted educational grants from Novartis, Takeda, and Abbott.